Bayesian estimation of doxorubicin pharmacokinetic parameters

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Biostatistics

Background:

• Doxorubicin is a vital chemotherapy agent with variable patient responses due to pharmacokinetic differences.
• Accurate individual pharmacokinetic parameter estimation is crucial for optimizing doxorubicin therapy.
• Traditional methods often require extensive blood sampling, increasing patient discomfort and cost.

Purpose of the Study:

• To develop and validate a Bayesian approach for estimating individual doxorubicin pharmacokinetic parameters.
• To assess the feasibility of using a reduced, sub-optimal blood sampling protocol.
• To compare the Bayesian estimation results with traditional maximal likelihood estimation.

Main Methods:

• A Bayesian pharmacokinetic model was developed and applied to 28 patients receiving doxorubicin.
• Population pharmacokinetic parameters were initially estimated from 19 patients (30 courses).
• Individual parameters were then estimated for 38 courses using a reduced sampling protocol (4 plasma concentrations).
• Bayesian estimates were compared to maximal likelihood estimates for accuracy and precision.

Main Results:

• No statistically significant differences were found between Bayesian and maximal likelihood estimations.
• The Bayesian method demonstrated acceptable bias and precision for key pharmacokinetic parameters (elimination phase, residual plasma level).
• The developed methodology allows for cost-effective and minimally invasive individual pharmacokinetic profiling.

Conclusions:

• The Bayesian approach provides a reliable and efficient method for estimating individual doxorubicin pharmacokinetics.
• This technique minimizes patient disturbance and healthcare costs associated with intensive blood sampling.
• The findings support the clinical utility of this Bayesian method for personalized chemotherapy dosing.